Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy

NCT04538625 is registered in ClinicalTrials.gov with Napo Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04538625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04538625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-blind Placebo-controlled Trial Evaluating Crofelemer for the Prophylaxis of Diarrhea in Adult Patients With Solid Tumors Receiving Targeted-cancer Therapies With or Without Standard Chemotherapy
Lead sponsor
Napo Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 7, 2020
Completion date
October 30, 2023
Enrollment
287 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid tumor, cancer therapy-related diarrhea, chemotherapy-related diarrhea, prophylaxis of diarrhea, symptomatic relief of diarrhea, targeted therapy-related diarrhea